{
    "clinical_study": {
        "@rank": "114236", 
        "arm_group": {
            "arm_group_label": "Guided Therapy- Pediatric Gene Analysis Platform", 
            "arm_group_type": "Experimental", 
            "description": "A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the feasibility (ability to be done) of experimental\n      technologies to determine a tumor's molecular makeup (gene expression profile) and\n      mutations.  This technology called the \"Pediatric Gene Analysis Platform\" includes a genomic\n      report (gene expression profile) and a DNA Mutation Panel Report that are being used to\n      discover new ways to understand cancers and potentially predict the best treatments for\n      patients with cancer in the future."
        }, 
        "brief_title": "Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuroblastoma", 
            "Medulloblastoma", 
            "Brain Tumors", 
            "Rare Tumors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Medulloblastoma", 
                "Neuroblastoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have histologically proven neuroblastoma, brain tumor, or rare tumor\n             and confirmation of refractory or recurrent disease with histologic confirmation at\n             diagnosis or at the time of recurrence/progression\n\n          -  Subjects must be age >12 months at enrollment.\n\n          -  Subjects must be age \u2264 21 years at initial diagnosis.\n\n          -  Subjects must have measurable disease as demonstrated by residual abnormal tissue at\n             a primary or metastatic site measuring more than 1 cm in any dimension by\n             standardized imaging (CT or MRI); tumor must be accessible for biopsy. Patients with\n             bone marrow only disease expected to be >75% tumor are eligible to enroll.\n\n          -  Current disease state must be one for which there is currently no known curative\n             therapy\n\n          -  Lansky or Karnofsky Score must be more than 50\n\n          -  Subjects without bone marrow metastases must have an ANC > 750/\u03bcl\n\n          -  Adequate liver function must be demonstrated, defined as:\n\n               1. Total bilirubin \u2264 1.5 x upper limit of normal (ULN) for age AND\n\n               2. SGPT (ALT) < 10 x upper limit of normal (ULN) for age\n\n          -  A negative serum pregnancy test is required for female participants of child bearing\n             potential (\u226513 years of age or after onset of menses)\n\n          -  Both male and female post-pubertal study subjects need to agree to use one of the\n             more effective birth control methods during treatment and for six months after\n             treatment is stopped. These methods include total abstinence (no sex), oral\n             contraceptives (\"the pill\"), an intrauterine device (IUD), levonorgestrol implants\n             (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of\n             these cannot be used, contraceptive foam with a condom is recommended.\n\n          -  Informed Consent: All subjects and/or legal guardians must sign informed written\n             consent. Assent, when appropriate, will be obtained according to institutional\n             guidelines. Voluntary consent for optional biology studies will be included.\n\n        Exclusion Criteria:\n\n          -  Subjects who have received any cytotoxic chemotherapy within the last 7 days prior to\n             enrollment and 14 days prior to study treatment start date.\n\n          -  Subjects who have received any radiotherapy to the primary sample site within the\n             last 14 days (radiation may be included in treatment decision after biopsy).\n\n          -  Subjects receiving anti-tumor therapy for their disease or any investigational drug\n             concurrently\n\n          -  Subjects with serious infection or a life-threatening illness (unrelated to tumor)\n             that is > Grade 2 (NCI CTCAE V4.0), or active, serious infections requiring\n             parenteral antibiotic therapy.\n\n          -  Subjects with any other medical condition, including malabsorption syndromes, mental\n             illness or substance abuse, deemed by the Investigator to be likely to interfere with\n             the interpretation of the results or which would interfere with a subject's ability\n             to sign or the legal guardian's ability to sign the informed consent, and subject's\n             ability to cooperate and participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Months"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802567", 
            "org_study_id": "NMTRC008"
        }, 
        "intervention": {
            "arm_group_label": "Guided Therapy- Pediatric Gene Analysis Platform", 
            "description": "A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).", 
            "intervention_name": "Guided Therapy- Pediatric Gene Analysis Platform", 
            "intervention_type": "Device", 
            "other_name": "Molecular Guided Therapy"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 5, 2014", 
        "link": {
            "description": "Neuroblastoma and Medulloblastoma Translational Research Consortium", 
            "url": "http://www.nmtrc.org"
        }, 
        "location": [
            {
                "contact": {
                    "email": "schimienti@phoenixchildrens.com", 
                    "last_name": "Samuel Chimienti", 
                    "phone": "602-546-0211"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Phoenix Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Francis Eshun, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mmilburn@rchsd.org", 
                    "last_name": "Mehrzad Milburn", 
                    "phone": "858-966-8155"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Rady Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "William Roberts, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jhylton02@connecticutchildrens.org", 
                    "last_name": "Jennifer Hylton", 
                    "phone": "860-545-9337"
                }, 
                "facility": {
                    "address": {
                        "city": "Hartford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06106"
                    }, 
                    "name": "Connecticut Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Nehal Parikh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michelle Pope, RN", 
                    "phone": "321-841-8588"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Arnold Palmer Hospital for Children- MD Anderson"
                }, 
                "investigator": {
                    "last_name": "Don Eslin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andrea.siu@kapiolani.org", 
                    "last_name": "Andrea Siu, MPH", 
                    "phone": "808-535-7169"
                }, 
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96813"
                    }, 
                    "name": "Kapiolani Medical Center for Women and Children"
                }, 
                "investigator": {
                    "last_name": "Randal Wada, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shannon.mackeigan@helendevoschildrens.org", 
                    "last_name": "Shannon Mackeigan", 
                    "phone": "616-267-1162"
                }, 
                "facility": {
                    "address": {
                        "city": "Grand Rapids", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49503"
                    }, 
                    "name": "Helen DeVos Children's Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Giselle Sholler, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Deanna Mitchell, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sjsoliman@cmh.edu", 
                    "last_name": "Sara Soliman, RN", 
                    "phone": "816-855-1977"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "Children's Mercy Hospitals and Clinics"
                }, 
                "investigator": {
                    "last_name": "Kathleen Neville, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Katherine Maxwell, RN", 
                    "phone": "314-268-4000"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63104"
                    }, 
                    "name": "Cardinal Glennon Children's Medical Center"
                }, 
                "investigator": {
                    "last_name": "William Ferguson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "felisha.turner@carolinashealthcare.org", 
                    "last_name": "Nicole Turner, RN", 
                    "phone": "980-442-2355"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "Levine Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Javier Oesterheld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mccormk@musc.edu", 
                    "last_name": "Kate McCormack, RN", 
                    "phone": "843-792-3379"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Jaqueline Kraveka, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "natalie.resczenko@Vanderbilt.Edu", 
                    "last_name": "Natalie Resczenko", 
                    "phone": "615-936-1522"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Valerie Brown, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lholden@sfcaustin.com", 
                    "last_name": "Letitia Holden, RN", 
                    "phone": "512-628-1902"
                }, 
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78723"
                    }, 
                    "name": "Dell Children's Blood and Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Sharon Lockhart, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lisa.Smith@imail.org", 
                    "last_name": "Lisa Smith", 
                    "phone": "801-662-4710"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84113"
                    }, 
                    "name": "Primary Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Mark Fluchel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer", 
        "overall_contact": {
            "email": "genevieve.bergendahl@helendevoschildrens.org", 
            "last_name": "Genevieve Bergendahl, RN", 
            "phone": "616-267-0335"
        }, 
        "overall_contact_backup": {
            "email": "alyssa.vanderwerff@helendevoschildrens.org", 
            "last_name": "Alyssa VanderWerff", 
            "phone": "(616) 267-0327"
        }, 
        "overall_official": {
            "affiliation": "The Spectrum Health Group", 
            "last_name": "Giselle Sholler, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The definition of feasibility for this study will include: \"Enrollment onto study, RNA expression profile completed, DNA Mutation Panel completed, genomic analysis and report generation, tumor board held with treatment decision, treatment review completed and start of treatment by 21 days post biopsy/surgical resection date, and then completion of 1 cycle of therapy.\"", 
            "measure": "Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic mRNA expression arrays and DNA Mutation Panels using predictive modeling", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802567"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Spectrum Health Hospitals", 
            "investigator_full_name": "Giselle Sholler", 
            "investigator_title": "Director of Pediatric Oncology Translational Research Program", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the safety of allowing a molecular tumor board to determine individualized treatment plans", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To determine the activity of treatments chosen based on Overall response rate (ORR) using RESIST criteria. The assessment of response will include the initial measurable targets and will be performed after cycle 2, then after every other cycle.", 
                "measure": "Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Duration of response, defined as the period of time from when measurement criteria are met for complete response (CR) or partial response (PR), whichever is first recorded, until the first date that recurrent or progressive disease (PD) is objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started)", 
                "measure": "Duration of response will be objectively documented", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To explore the relationship between tumor phenotype and response by permitting use of tumor tissue in a correlative biologic study", 
                "measure": "Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, flow cytometry of tumor burden in bone marrow and biomarker development", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Time to progression (PFS), defined as the period from the start of the treatment until the criteria for progression are met taking as reference the screening measurements", 
                "measure": "Progression Free Survival (PFS) interval will be measured by days and compared to the PFS of previous chemotherapy regimens since relapse for each patient.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Spectrum Health Hospitals", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Van Andel Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dell, Inc.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Giselle Sholler", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}